The Melanoma Research Alliance's 2026 survey of 2,000 adults reveals only 38% apply sunscreen during routine activities despite 80% awareness of sun risks, yet this observational snapshot (margin of error ±2%) understates deeper systemic issues. An Australian RCT (Green et al., JAMA 2011, n=1,621, low bias, no industry conflicts) demonstrated daily broad-spectrum SPF 16+ reduced invasive melanoma incidence by 50% over 10 years, a finding corroborated by observational SEER data showing U.S. rates rising 3% annually since 2010 amid inconsistent FDA labeling and social media chemophobia affecting 60% of respondents. The coverage misses how 33% of Black participants' misconceptions align with darker-skin melanoma underdiagnosis patterns in cohort studies (e.g., American Cancer Society analyses), while mixed messaging from influencers overrides peer-reviewed efficacy data. Public health failures compound as no large-scale U.S. equivalent to the Nambour trial exists, leaving projected 10%+ case increases in 2026 unaddressed despite SPF 30+ UVA/UVB recommendations.